Avidity Biosciences (RNA) Stock Statistics & Valuation Metrics

Avidity Biosciences has a market cap or net worth of $10.78B. The enterprise value is $4.18B.

Avidity Biosciences has 150,675,740 shares outstanding. The number of shares has decreased by -2.65% in one year.

Avidity Biosciences’s return on equity (ROE) is -0.23 and return on invested capital (ROIC) is -25.78%.

The current PE Ratio of Avidity Biosciences is ―. Avidity Biosciences’s PEG ratio is 14.65.

In the last 12 months, Avidity Biosciences had revenue of 10.90M and earned -322.30M in profits. Earnings per share was -2.89.

In the last 12 months, operating cash flow was -580.54M and capital expenditures -14.90M, giving a free cash flow of -595.44M billion.

Avidity Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Avidity Biosciences upcoming earnings date is Mar 3, 2026, After Close (Confirmed).

Avidity Biosciences as a current ratio of 15.73, with Debt / Equity ratio of 0.43%

In the past 12 months, Avidity Biosciences has paid 0.00 in taxes.

Avidity Biosciences EV to EBITDA ratio is -8.06, with an EV/FCF ratio of -9.85.

Avidity Biosciences has $1.88B in cash and marketable securities with $49.97M in debt, giving a net cash position of $1.83B billion.

Gross margin is 92.41%, with operating margin of -3477.43%, and net profit margin of -2957.71%.

The average price target for Avidity Biosciences is $71.71, which is 11.43% higher than the current price. The consensus rating is Moderate Buy